Alzamend Neuro, Inc. filed its fiscal 2026 Annual Report for the year ending April 30, 2026. The company expects topline results for its AL001 Phase II Bipolar Disorder trial in Q4 2026. Its ALZN002 cell-based vaccine Phase I/IIA trial is currently delayed.
The company reported zero product revenue for the fiscal year. Net loss totaled $8.77 million, representing a loss of $2.63 per share.
Management indicated that current cash reserves are insufficient to fund operations for the next 12 months. The company requires additional funding to support ongoing trials and planned expansion. The report also identified a material weakness in internal controls over financial reporting.